Inhibrx Biosciences (INBX) Income towards Parent Company (2023 - 2026)

Inhibrx Biosciences (INBX) has reported Income towards Parent Company for 3 consecutive years, with -$32.8 million the latest figure, recorded in Q4 2025.

• In Q4 2025, Income towards Parent Company rose 31.4% year-over-year to -$32.8 million; the TTM figure through Dec 2025 stood at -$140.1 million (down 108.3% YoY), while the FY2025 annual figure was -$140.1 million, down 108.3% from the prior year.
• Income towards Parent Company advanced to -$32.8 million in Q4 2025 per INBX's latest filing, from -$35.3 million in the prior quarter.
• Across five years, Income towards Parent Company topped out at $1.9 billion in Q2 2024 and bottomed at -$92.0 million in Q4 2023.
• Historically, Income towards Parent Company has averaged $123.3 million across 3 years, with a median of -$43.9 million in 2024.
• Annual changes were most pronounced in 2024 — Income towards Parent Company soared 4048.85% — and 2025, when it plunged 101.54%.
• Inhibrx Biosciences' Income towards Parent Company stood at -$92.0 million in 2023, then soared by 47.96% to -$47.9 million in 2024, then jumped by 31.4% to -$32.8 million in 2025.
• Business Quant data shows INBX's Income towards Parent Company at -$32.8 million in Q4 2025, -$35.3 million in Q3 2025, and -$28.7 million in Q2 2025.